Arcturus Therapeutics(ARCT) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Year-over-year annual revenue decreased by $70.3 million, and quarterly revenue decreased by $15.6 million, primarily due to reduced revenue from the CSL collaboration and lower milestone achievements as KOSTAIVE was commercialized [13][14] - Research and development expenses decreased by $83.0 million annually and $19.3 million quarterly, driven by lower manufacturing and clinical costs related to the LUNAR-COV19 program transitioning to commercial phase [14] - General and administrative expenses decreased by $6.7 million annually but increased by $1.6 million quarterly due to accelerated employee stock options [15] Business Line Data and Key Metrics Changes - The ARCT-032 program for cystic fibrosis is progressing with a phase 2 trial set to initiate in the first half of 2026, focusing on higher dose testing and evaluating safety and early clinical benefits [5][10] - The ARCT-810 program for ornithine transcarbamylase deficiency is advancing towards pivotal development, with regulatory meetings scheduled for the first half of 2026 to clarify clinical development strategies [6][12] Market Data and Key Metrics Changes - The KOSTAIVE COVID-19 vaccine received approval from the UK Medicines and Healthcare Products Regulatory Agency for individuals aged 18 and older, marking a significant milestone for the company [6] Company Strategy and Development Direction - The company is focusing on rare disease clinical programs and has extended its cash runway into the second quarter of 2028, indicating a strong financial position to achieve near-term milestones [16] - The strategy includes optimizing clinical study designs, such as the 12-week study for ARCT-032, to enhance the reliability of results and patient enrollment [21][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming clinical studies and the potential for meaningful clinical data in 2026, particularly for the cystic fibrosis and OTC deficiency programs [5][12] - The company is actively engaging with regulatory authorities to clarify study designs and endpoints, especially for the pediatric population in the OTC deficiency program [47][60] Other Important Information - The company is involved in ongoing litigation against AbbVie and Capstan Therapeutics, which may impact future operations [7] - The management highlighted the importance of collaboration with the CF Foundation to enhance patient enrollment and study design [24] Q&A Session Summary Question: What optimizations were included in the 12-week phase II study compared to the initial study? - Management highlighted differences in study design, including stable baseline measures and the inclusion of Lung Clearance Index to enhance reproducibility [20][21] Question: How sensitive is the Lung Clearance Index (LCI) test? - LCI is noted to be more sensitive and less variable than traditional spirometry, making it a preferred measure for children and early changes in lung function [28][29] Question: What is the rationale for stopping at 15 milligrams for the CF program? - The company has flexibility to increase dosing if needed, but is currently focused on the 10-milligram dose based on early efficacy signals [45][71] Question: What are the expected outcomes from regulatory discussions for the OTC program? - The goal is to establish a clear path forward with agreed endpoints for both pediatric and adult populations, with a focus on high unmet medical needs [60][61] Question: What updates are there on the COVID-19 vaccine initiatives? - Progress has been made for KOSTAIVE in the UK, but challenges remain for approval in the U.S. due to the current administration's stance [62]